Actinogen Medical (ASX: ACW)

Last close As at 21/02/2025

AUD0.04

0.00 (−2.63%)

Market capitalisation

AUD120m

Actinogen Medical is an ASX-listed Australian biotech developing its lead asset Xanamem, a specific and selective 11beta-HSD1 inhibitor designed to treat cognitive impairment (CI), which occurs in chronic neurodegenerative and neuropsychiatric diseases.

Latest Insights

View More

Healthcare | Update

Actinogen Medical — XanaMIA Phase IIb/III study marches on

Healthcare | edison tv

Actinogen Medical – executive interview

Healthcare | Update

Actinogen Medical — A$11.1m capital raise completed

Actinogen Medical

Sector

Healthcare

Equity Analyst

Pooya Hemami, OD MBA, CFA

Analyst - Healthcare

Jyoti Prakash

Jyoti Prakash, CFA

Analyst, Healthcare

Key Management

  • Dr Steven Gourlay

    CEO and MD

  • Michael Roberts

    Head of investor relations

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free